Study · Randomized controlled trial · n = 90 · 2016

4 results

Effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction.

Chen WR, Shen XQ, Zhang Y, Chen YD, Hu SY, Qian G, Wang J, Yang JJ, Wang ZF, Tian F

Endocrine16 Nov 2015Cited by 69 (Europe PMC)

PMID26573925DOI10.1007/s12020-015-0798-0PepBankPUB-26573925

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with NSTEMI, liraglutide for 7 days increased the 3-month change in left ventricular ejection fraction by 4.7% compared with placebo.
In plain wordsIn patients with a heart attack of the NSTEMI type, liraglutide improved heart pumping function at 3 months more than placebo.
Peptide
Liraglutide
Outcome
IncreaseChange in left ventricular ejection fraction at 3 months
Study
n = 90
Comparator
Placebo
Analysis
Primary
Outcome group
Heart function · Cardiovascular
Studied dose
0.6 mg for 2 days, 1.2 mg for 2 days, then 1.8 mg for 3 days · 7 daysAs given in this study (human).
Measurements
Difference in LVEF change
4.7%
liraglutide vs placebo
Source sentences
Summary
At 3 months, the primary endpoint, the difference in the change in left ventricular ejection fraction between the two groups was +4.7 % (liraglutide vs. placebo 95 % CI +0.7 to +9.2 % P = 0.009) under intention-to-treat analysis.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 90 patients were randomized 1:1 to receive either liraglutide (0.6 mg for 2 days, 1.2 mg for 2 days, followed by 1.8 mg for 3 days) or placebo for 7 days.
Report a problemFND-2657392501
02HumanRandomized controlled trialEfficacy outcome
In patients with NSTEMI, liraglutide decreased serum glycosylated hemoglobin by 0.2% more than placebo.
In plain wordsIn patients with a heart attack of the NSTEMI type, liraglutide lowered HbA1c slightly more than placebo.
Peptide
Liraglutide
Outcome
DecreaseChange in serum glycosylated hemoglobin
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.6 mg for 2 days, 1.2 mg for 2 days, then 1.8 mg for 3 days · 7 daysAs given in this study (human).
Measurements
Difference in HbA1c decrease
−0.2%
liraglutide vs placebo
Source sentences
Summary
The difference in decrease in serum glycosylated hemoglobin levels was -0.2 % (liraglutide vs. placebo 95 % CI -0.1 to -0.3 %; P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 90 patients were randomized 1:1 to receive either liraglutide (0.6 mg for 2 days, 1.2 mg for 2 days, followed by 1.8 mg for 3 days) or placebo for 7 days.
Report a problemFND-2657392502
03HumanRandomized controlled trialMechanism
In patients with NSTEMI, inflammation improved significantly in the liraglutide group compared with the placebo group.
In plain wordsIn patients with a heart attack of the NSTEMI type, signs of inflammation improved more with liraglutide than with placebo.
Peptide
Liraglutide
Outcome
Direction not reportedInflammation markers
Study
n: not reported in source
Comparator
Placebo
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
0.6 mg for 2 days, 1.2 mg for 2 days, then 1.8 mg for 3 days · 7 daysAs given in this study (human).
Source sentences
Summary
Inflammation and oxidative stress improved significantly in the liraglutide group compared to the placebo group.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 90 patients were randomized 1:1 to receive either liraglutide (0.6 mg for 2 days, 1.2 mg for 2 days, followed by 1.8 mg for 3 days) or placebo for 7 days.
Report a problemFND-2657392503
04HumanRandomized controlled trialMechanism
In patients with NSTEMI, oxidative stress improved significantly in the liraglutide group compared with the placebo group.
In plain wordsIn patients with a heart attack of the NSTEMI type, signs of oxidative stress improved more with liraglutide than with placebo.
Peptide
Liraglutide
Outcome
Direction not reportedOxidative stress markers
Study
n: not reported in source
Comparator
Placebo
Outcome group
Oxidative stress · Cardiovascular
Studied dose
0.6 mg for 2 days, 1.2 mg for 2 days, then 1.8 mg for 3 days · 7 daysAs given in this study (human).
Source sentences
Summary
Inflammation and oxidative stress improved significantly in the liraglutide group compared to the placebo group.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 90 patients were randomized 1:1 to receive either liraglutide (0.6 mg for 2 days, 1.2 mg for 2 days, followed by 1.8 mg for 3 days) or placebo for 7 days.
Report a problemFND-2657392504

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · source ClinicalTrials.gov (opens in a new tab)

Status unknownNot applicableNCT02930265

Clinical Study of Liraglutide in Improving Cardiac Function for Patients With Ischemic Cardiomyopathy

Chinese PLA General Hospitaln = 400Sept 2016 to est. Mar 2018

Ischemic Cardiomyopathy

Trial page ClinicalTrials.govUpdated 12 Oct 2016

Status unknownNot applicableNCT02650596

Effects of GLP-1 on Chronic Heart Failure

Shi Yangn = 68Jan 2016 to est. Feb 2018

Heart Failure

Trial page ClinicalTrials.govUpdated 8 Jan 2016

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.